Last updated on August 2018

Prospective Evaluation of the Efficacy of Sirolimus (Rapamune ) in the Treatment of Severe Arteriovenous Malformations

Brief description of study

The aim of the study is to evaluate the efficacy and safety of sirolimus (oral form), to decrease the volume and symptoms due to superficial arteriovenous malformations (AVM).

Sirolimus has properties that reduce the activity of the immune system (immunosuppressant), to fight against the proliferation of cancer cells (anti- tumor) and also reduce the proliferation of blood vessels (anti -vascular). Sirolimus is primarily used in transplant patients to prevent organ transplant rejection. Many animal and laboratory studies were carried out and demonstrate in particular the activity of sirolimus on vessels. It is this anti- vascular effect that could help treat arteriovenous malformations.

Detailed Study Description

Anti-proliferative and anti-angiogenic properties of Sirolimus (Rapamycin) are the basis of the rationale to use it in the treatment of arteriovenous malformations, for which the pathophysiology remains poorly understood. The interest of this class of drug is that inhibition of mTOR (mammalian target of rapamycin) may also block growth and / or angiogenic factors (other than VEGF) involved in the development of AVM. More specifically anti-VEGF drugs does not have that potential.

Clinical Study Identifier: NCT02042326

Find a site near you

Start Over

CHU Amiens

Amiens, France
  Connect »